
UK Standards for Microbiology Investigations

Investigation of Throat Related Specimens



Acknowledgments

UK Standards for Microbiology Investigations (SMIs) are developed under the auspices of Public Health England (PHE) working in partnership with the National Health Service (NHS), Public Health Wales and with the professional organisations whose logos are displayed below and listed on the website <http://www.hpa.org.uk/SMI/Partnerships>. SMIs are developed, reviewed and revised by various working groups which are overseen by a steering committee (see <http://www.hpa.org.uk/SMI/WorkingGroups>).

The contributions of many individuals in clinical, specialist and reference laboratories who have provided information and comments during the development of this document are acknowledged. We are grateful to the Medical Editors for editing the medical content.

For further information please contact us at:

Standards Unit

Microbiology Services

Public Health England

61 Colindale Avenue

London NW9 5EQ

E-mail: [standards@phe.gov.uk](mailto:standards@phe.gov.uk)

Website: <http://www.hpa.org.uk/SMI>

UK Standards for Microbiology Investigations are produced in association with: 

Contents

Acknowledgments 2

Amendment Table 4

UK SMI: Scope and Purpose 5

Scope of Document 7

Scope 7

Introduction 7

Technical Information/Limitations 14

1 Safety Considerations 16

2 Specimen Collection 16

3 Specimen Transport and Storage 17

4 Specimen Processing/Procedure 17

5 Reporting Procedure 21

6 Notification to PHE or Equivalent in the Devolved Administrations 21

Appendix: Investigation of Throat Related Specimens 23

References 24



Amendment Table

Each SMI method has an individual record of amendments. The current amendments are listed on this page. The amendment history is available from [standards@phe.gov.uk](mailto:standards@phe.gov.uk).

New or revised documents should be controlled within the laboratory in accordance with the local quality management system.

|  |  |
| --- | --- |
| Amendment No/Date. | / |
| Issue no. discarded. |  |
| Insert Issue no. | xx |
| **Section(s) involved** | **Amendment** |

|  |  |
| --- | --- |
|  |  |

|  |  |
| --- | --- |
| Amendment No/Date. | / |
| Issue no. discarded. |  |
| Insert Issue no. | #.# <tab+enter> |
| **Section(s) involved** | **Amendment** |
| Xxxxxx | xxxxxx |
| Xxxxxxx | xxxxxx |
| Xxxxxxx | xxxxxx |
|  |  |

UK SMI[[1]](#footnote-1)#: Scope and Purpose

Users of SMIs

Primarily, SMIs are intended as a general resource for practising professionals operating in the field of laboratory medicine and infection specialties in the UK. SMIs also provide clinicians with information about the available test repertoire and the standard of laboratory services they should expect for the investigation of infection in their patients, as well as providing information that aids the electronic ordering of appropriate tests. The documents also provide commissioners of healthcare services with the appropriateness and standard of microbiology investigations they should be seeking as part of the clinical and public health care package for their population.

Background to SMIs

SMIs comprise a collection of recommended algorithms and procedures covering all stages of the investigative process in microbiology from the pre-analytical (clinical syndrome) stage to the analytical (laboratory testing) and post analytical (result interpretation and reporting) stages. Syndromic algorithms are supported by more detailed documents containing advice on the investigation of specific diseases and infections. Guidance notes cover the clinical background, differential diagnosis, and appropriate investigation of particular clinical conditions. Quality guidance notes describe laboratory processes which underpin quality, for example assay validation.

Standardisation of the diagnostic process through the application of SMIs helps to assure the equivalence of investigation strategies in different laboratories across the UK and is essential for public health surveillance, research and development activities.

Equal Partnership Working

SMIs are developed in equal partnership with PHE, NHS, Royal College of Pathologists and professional societies. The list of participating societies may be found at <http://www.hpa.org.uk/SMI/Partnerships>. Inclusion of a logo in an SMI indicates participation of the society in equal partnership and support for the objectives and process of preparing SMIs. Nominees of professional societies are members of the Steering Committee and Working Groups which develop SMIs. The views of nominees cannot be rigorously representative of the members of their nominating organisations nor the corporate views of their organisations. Nominees act as a conduit for two way reporting and dialogue. Representative views are sought through the consultation process. SMIs are developed, reviewed and updated through a wide consultation process.

Quality Assurance

NICE has accredited the process used by the SMI Working Groups to produce SMIs. The accreditation is applicable to all guidance produced since October 2009. The process for the development of SMIs is certified to ISO 9001:2008. SMIs represent a good standard of practice to which all clinical and public health microbiology laboratories in the UK are expected to work. SMIs are NICE accredited and represent neither minimum standards of practice nor the highest level of complex laboratory investigation possible. In using SMIs, laboratories should take account of local requirements and undertake additional investigations where appropriate. SMIs help laboratories to meet accreditation requirements by promoting high quality practices which are auditable. SMIs also provide a reference point for method development. The performance of SMIs depends on competent staff and appropriate quality reagents and equipment. Laboratories should ensure that all commercial and in-house tests have been validated and shown to be fit for purpose. Laboratories should participate in external quality assessment schemes and undertake relevant internal quality control procedures.

Patient and Public Involvement

The SMI Working Groups are committed to patient and public involvement in the development of SMIs. By involving the public, health professionals, scientists and voluntary organisations the resulting SMI will be robust and meet the needs of the user. An opportunity is given to members of the public to contribute to consultations through our open access website.

Information Governance and Equality

PHE is a Caldicott compliant organisation. It seeks to take every possible precaution to prevent unauthorised disclosure of patient details and to ensure that patient-related records are kept under secure conditions. The development of SMIs are subject to PHE Equality objectives <http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1317133470313>.

The SMI Working Groups are committed to achieving the equality objectives by effective consultation with members of the public, partners, stakeholders and specialist interest groups.

Legal Statement

Whilst every care has been taken in the preparation of SMIs, PHE and any supporting organisation, shall, to the greatest extent possible under any applicable law, exclude liability for all losses, costs, claims, damages or expenses arising out of or connected with the use of an SMI or any information contained therein. If alterations are made to an SMI, it must be made clear where and by whom such changes have been made.

The evidence base and microbial taxonomy for the SMI is as complete as possible at the time of issue. Any omissions and new material will be considered at the next review. These standards can only be superseded by revisions of the standard, legislative action, or by NICE accredited guidance.

SMIs are Crown copyright which should be acknowledged where appropriate.

Suggested Citation for this Document

Public Health England. (). Investigation of Throat related specimens. UK Standards for Microbiology Investigations. B 9 Issue #.# <tab+enter>. <http://www.hpa.org.uk/SMI/pdf>

Scope of Document

Type of Specimen

Throat swab, posterior pharyngeal swab, nasopharyngeal swab, pharyngeal washings, pus aspirate, oropharyngeal swab, throat gargle

Scope

This SMI describes the examination of bacteria and fungi from throat related specimens known to cause upper respiratory tract infections.

For more information, refer to

[ID 6 – Identification of *Neisseria* species](http://www.hpa.org.uk/SMI/pdf/identification)

[B 51- Screening for](http://www.hpa.org.uk/SMI/pdf/bacteriology) *[Neisseria meningitidis](http://www.hpa.org.uk/SMI/pdf/bacteriology)*

[B 29 - Investigation of Specimens for Screening for MRSA,](http://www.hpa.org.uk/SMI/pdf/bacteriology) and

[B 14 - Investigation of Abscesses and Deep-Seated Wound Infections.](http://www.hpa.org.uk/SMI/pdf/Bacteriology)

For viruses that may be isolated from throat swabs, refer to [G 8 – Respiratory Viruses](http://www.hpa.org.uk/SMI/pdf/clinicalguidance).

This SMI should be used in conjunction with other SMIs.

Introduction

Throat related specimens are one of the most commonly performed procedures in patients with upper respiratory tract infections. This is usually carried out in primary care facilities and in emergency departments.

Upper respiratory tract infections are classified according to the type of inflammation they cause. As with many infections, the primary challenge in these conditions lies in identifying the causative pathogen and determining the extent of disease progression. There are several types of inflammation of the upper respiratory tract and they are as follows1,2:

* Pharyngitis (also known as sore throat)
* Tonsillitis
* Epiglottitis
* Laryngitis

Pharyngitis1,2

Pharyngitis is inflammation of the pharynx. It is also known as “sore throat”. This infection may be acute or chronic. Most cases are caused by viruses but it can also be caused by bacteria. Clinically, it is difficult to differentiate between bacterial and viral cause of pharyngitis based on symptoms alone. The typical symptoms are a sore throat, fever and headache but may be associated with nausea and vomiting, abdominal pain, muscle pain, scarlet fever and rashes.

Organisms commonly isolated from pharyngitis are as follows;

**Streptococci**

The most common cause of bacterial pharyngitis is the Lancefield group A, *Streptococcus pyogenes*. Healthy carriers of group A streptococci are usually children in whom rates of up to 20% - 30% have been reported, but rates are much lower in adults (5% - 15%)3. In these individuals isolation of Lancefield group A streptococci does not necessarily imply a role in infection.

Extrapharyngeal manifestations of Lancefield group A streptococcus infection can be divided into those associated with acute infection and the nonsuppurative post streptococcal sequelae such as acute rheumatic fever and glomerulonephritis, which occur 2-3 weeks after pharyngeal infection4. In acute infection, bacteraemia and streptococcal toxic shock may occur. Post streptococcal sequelae appear to be limited to a circumscribed set of serotypes5.

Lancefield group C streptococci have been reported as a cause of pharyngitis 6. The majority of the species, however, are zoonotic and rarely cause disease in humans; these include *Streptococcus equi* subspecies *zooepidemicus, Streptococcus equi* subspecies *equi* and *Streptococcus dysgalactiae* subspecies *dysgalactiae*. The beta-haemolytic group C streptococci infecting humans include the large colony form *Streptococcus dysgalactiae* subspecies *equisimilis* and the minute colony form or *Streptococcus anginosus* group (formerly the *S. milleri* group), which includes *Streptococcus constellatus* subspecies *pharyngis* and *Streptococcus anginosus*. These organisms are very rarely implicated in bacterial pharyngitis, and may express A, C, F or G Lancefield group antigens. The Lancefield group G streptococci are known to cause pharyngitis and are subdivided into the "large colony" form (which comprises the animal species *Streptococcus canis* and the human species *Streptococcus dysgalactiae* subspecies *equisimilis*, which is the only recognised causative agent of pharyngitis within the group) and the "minute colony" form (*S. anginosus*)7.

Most of the evidence for Lancefield groups C and G streptococci causing pharyngitis comes from reports of outbreaks8-11.

***Corynebacterium diphtheriae***

Diphtheria is an acute infectious disease of the upper respiratory tract and occasionally the skin. It is caused by toxigenic strains of *Corynebacterium diphtheriae* (of which there are 4 biotypes - *gravis, mitis, intermedius* and *belfanti*) and some toxigenic strains of *Corynebacterium ulcerans* and *Corynebacterium pseudotuberculosis*12. All can carry the phage-borne diphtheria toxin gene. In a fully developed case of diphtheria, this toxin damages the pharyngeal epithelium to produce a leathery membrane, giving the disease its name. This membrane may occlude the airway, sometimes causing death by respiratory obstruction. Systemic absorption by the host of the toxin from the primary site of replication may damage a wide range of cells, including those of the heart and nervous system. Myocarditis and neurological dysfunction may cause or contribute to disability or death.

The usual site of carriage or infection is the throat or nasopharynx, occasionally the nose.

Mild cases of the disease resemble streptococcal pharyngitis and the classic pseudomembrane of the pharynx may be lacking. It is thought that *C. diphtheriae* has additional virulence factors because invasive disease caused by non-toxigenic strains has been reported13,14. Non-toxigenic strains of *C. diphtheriae* may be encountered in clinical specimens, especially those taken from persons previously immunised against diphtheria toxin. Non-toxigenic *C. diphtheriae* has been suggested as a cause of sore throat, but does not cause a true diphtheritic membrane or symptoms attributable to systemic absorption of toxin12. On re-introduction of the necessary gene, these organisms may, however, express toxin production. There is a suggestion that particular clones of non-toxigenic *C. diphtheriae* may be especially virulent as described from Russia and other former Soviet states15,16. Occasionally, humans will develop invasive infections with non-toxigenic strains of *C. diphtheriae*13,14. These conditions appear to be rare, and will be detected by blood culture rather than by culture of throat or nasopharyngeal swabs.

Although toxigenic *C. ulcerans* generally causes mild pharyngitis without any associated sequelae, at least as many cases of clinical diphtheria are now caused by *C. ulcerans* as by *C. diphtheriae* in England and Wales since the 1990s17,18. There is no direct evidence of person-to-person transmission of *C. ulcerans*, but it is thought that this may occur. *C. ulcerans* may infect the bovine udder and an association between human *C. ulcerans* infection and drinking raw milk has been observed19. However, molecular studies have indicated that domestic animals (livestock, pet cats and dogs) may be a more likely source of infection20-23.

The pathogenic mechanism is unclear. However, as a consequence of the genome sequence being published, genes encoding adhesins, fimbriae and other products have now been identified and are thought to contribute towards pathogenicity24.

Non-toxigenic strains in pharyngeal flora have the potential to undergo lysogenic conversion to toxin production in vivo, which may lead to disease25.

In the 1990s there was an increase in the incidence of diphtheria in Russia and other former Soviet states, although the situation is now improving26. Diphtheria cases have continued to be reported from every WHO Region, especially the higher risk regions eg Africa, South East Asia and South America. Following enhancement or introduction of appropriate Public Health interventions, such as immunisation, case-finding and treatment of cases and carriers within these countries, there is now evidence that the situation has improved but there is still a strong need to maintain microbiological surveillance, laboratory expertise and an awareness of these organisms amongst public health specialists, microbiologists and clinicians26-28.

In a susceptible population the introduction of a toxigenic strain can result in direct spread by droplet infection. Mass immunisation has resulted in the virtual disappearance of toxigenic *C. diphtheriae* from the United Kingdom, but it might not have affected the carriage of non-toxigenic strains. Most cases of toxigenic *C. diphtheriae* reported in the UK are imported from South East Asia and the Indian sub-continent and these diphtheria cases continue to be reported in South-East Asia, South America, Africa and India. A large number of UK citizens travel to and from these regions, maintaining the possibility of the reintroduction of *C. diphtheriae* into the UK29. However, according to the UK schedule, all travellers to epidemic or endemic areas should ensure that they are fully immunised. It also highlights the need to maintain UK routine vaccination coverage at the 95% level in the UK as recommended by the World Health Organization17,29.

**Note:** For more information on the new diphtheria guidelines, see the Public Health Control and Management of Diphtheria in England and Wales publication. The guidelines are available on the HPA legacy website diphtheria guidelines page: <http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1317141014343>.

**Criteria for screening throat swabs for *C. diphtheriae***

There are specific clinical associations and exposures which, if reported on requests, should trigger examination of specimens for *C. diphtheriae* or *C. ulcerans*. These are based on recognised risk factors and information from enhanced diphtheria surveillance. For more on relevant information that requests may have, see [ID 2 – Identification of *Corynebacterium* species.](http://www.hpa.org.uk/SMI/pdf/identification)

However, this SMI recommends screening for *Corynebacterium* species in the following circumstances:

**Throat (or nose) swabs from a patient with one or more of the following risk factors reported:**

* Membranous or pseudomembranous pharyngitis/tonsillitis
* Immunisation history (primary course and boosters, including dates)
* Contact with a confirmed case within the last 10 days
* Travel abroad to high risk area within the last 10 days
* Contact with someone who has been to a high risk area within the last 10 days
* Contact with any animals (including household pets, visiting a farm or petting zoo) (*C. ulcerans*) within the last 10 days
* Recent consumption of any type of unpasteurised milk or dairy products (*C. ulcerans*)
* The patient works in a clinical microbiology laboratory, or similar occupation, where *Corynebacterium* species may be handled

It is recommended that those laboratories with a specific public health remit, such as Public Health England laboratories, continue to screen all throat swabs for *Corynebacterium* species: this ensures that surveillance of the disease continues and appropriate public health action is taken.

Other causes of pharyngitis

**Vincent’s angina**

*Borrelia vincentii* and *Fusobacterium* species are associated with the infection known as Vincent's angina. It is characterised by ulceration of the pharynx or gums and occurs in adults with poor mouth hygiene or serious systemic disease30.

***Arcanobacterium haemolyticum* (previously *Corynebacterium haemolyticum*)**

Although *Arcanobacterium haemolyticum* is recognised as a human pathogen, this SMI does not recommend routine investigation for the organism. It has been associated with tonsillitis, pharyngitis and may cause a rash in young adults and occasionally in children16,31. It is suggested that in cases of treatment failure and recurrent tonsillitis, isolation of *A. haemolyticum* should be considered.

After 48hr incubation on blood agar, *A. haemolyticum* colonies exhibit narrow zones of ß-haemolysis and are approximately 0.5mm in diameter. In cases where *A. haemolyticum* is suspected, incubation of culture plates may need to be extended up to 72hr. The organism's presence may be indicated by the pitting of the agar underneath the colony; when the colony is pushed aside a minute dark pit is revealed32.

**Fungal throat and pharyngeal infections**

These infections are common in patients who are immunocompromised, particularly during episodes of severe neutropenia. Patients receiving antibiotics are also prone to fungal infections. *Candida* species may rarely cause severe invasive oesophagitis which can result in desquamation and expulsion of tissue33. Recognition of oropharyngeal candidosis accompanied by dysphagia indicate the possibility of oesophageal candidosis and this may be an AIDS-defining illness34,35. Yeast and fungal isolates from patients who are immunocompromised usually require identification and susceptibility testing.

***Fusobacterium necrophorum***

*Fusobacterium necrophorum* infection may be characterised by acute pharyngitis and fever, sometimes accompanied by membranous tonsillitis30. In the absence of therapy, a small number of these patients may develop the bacteraemia and metastatic infection characteristic of Lemièrre’s disease, which can be life threatening36.

*Fusobacterium necrophorum* has been isolated in cases of recurrent or persistent sore throat, and is a common cause of peritonsillar abscess or quinsy37. It is believed that up to half a million patients may present with pharyngitis due to this organism annually38. The literature, however, also suggests that the organism may form a minor part of the normal microflora of the upper airways in some individuals, although it has proven to be difficult to obtain primary evidence for this36,38.

***Neisseria gonorrhoeae***

Pharyngeal specimens contain a variety of microorganisms including saprophytic *Neisseria* species. Identification of *Neisseria gonorrhoeae* from extragenital sites such as the oropharynx must be carefully performed and checked as a positive result can have important clinical and medico-legal implications (refer to [ID 6 – Identification of *Neisseria* species](http://www.hpa.org.uk/SMI/pdf/identification)). Pharyngeal colonisation may be found in patients with genital gonorrhoea, but the pharynx is rarely the only infected site39.

**Rare causes of Pharyngitis**

***Francisella tularensis***

Oropharyngeal tularaemia (Type B tularaemia) is contracted by ingestion of contaminated food or water and it presents as stomatitis and pharyngitis. The primary ulcer is localised in the mouth, and lymph nodes of the neck region are enlarged. Physical examination shows redness and pustular changes in the mouth and pharyngeal mucous membranes, together with enlargement of regional neck lymph nodes. If tularaemia is not suspected for epidemiological reasons, the diagnosis will most likely be missed and appropriate therapy not prescribed. Identification of *Francisella tularensis* from oropharyngeal specimens should be carefully done in a microbiological safety cabinet level 2 whereas work on colonies and manipulations that might involve aerosol formation requires biological safety cabinet level 3 conditions40.

For diagnosis, culture is more often performed for type B tularaemia in regions where this is endemic. It can be grown from pharyngeal washings, sputum specimens, and even fasting gastric aspirates in a high proportion of patients with inhalational tularaemia. It is only occasionally isolated from blood. When growth of *F. tularensis* is suspected, a reference laboratory should be consulted for safe handling and further identification.

Tularaemia occurs endemically in most countries of the Northern hemisphere, within a range of 30 to 71° latitude. The countries where the disease has been reported are Canada, the USA and Japan. Tularaemia is widely distributed over the Eurasian continent. A high prevalence is found in the former Soviet Union and the Nordic countries, whereas the British Islands seem to be free from the disease41.

***Yersinia enterocolitica***

*Y. enterocolitica* commonly causes enteric infections but may also infect other body sites such as lungs, bone joints, etc. Although rare, this organism has been responsible for some sporadic cases of pharyngitis. This has been isolated from throats of patients with enteritis from an outbreak due to contaminated pasteurised milk42,43. The signs and symptoms are characterised by sore throat and fever without enteritis.

Throat swabs may be used to investigate carriage of *Yersinia enterocolitica* in patients42.

**Other uncommon organisms**

Pathogens such as *Mycoplasma pneumoniae* and *Chlamydophila pneumoniae* are also uncommon causes of acute pharyngitis3.

**Screening for carriage in contacts**

***Neisseria meningitidis***

*Neisseria meningitidis* can be spread from carrier to carrier, probably via the oral-respiratory route. A susceptible person is at risk when close contacts such as family members are identified as carriers44.

*N. meningitidis* is carried on the posterior pharyngeal wall and can be detected from oropharyngeal or nasopharyngeal swabs45. However, posterior pharyngeal swabs seem to be better than nasopharyngeal swabs for detecting *N. meningitidis* carriage in large epidemiological studies because they identify a significantly larger number of pathogen carriers and recover a significantly larger amount of bacterial DNA46. Throat swabs may be an aid to diagnosis of meningococcal meningitis47. *N. meningitidis* can be isolated from a throat swab in about half the cases of invasive meningococcal disease (refer to [B 51 - Screening for *Neisseria meningitidis*](http://www.hpa.org.uk/SMI/pdf/bacteriology)). The strain isolated from the throat is likely to be of the same group and type as that isolated from cerebrospinal fluid and blood44. However, other reports have described throat swabs from contacts as having no value as an aid to diagnosis because the strains from contacts are often different from those isolated from index cases48-50.

***Staphylococcus aureus***

Throat swabs may be used to investigate carriage of *Staphylococcus aureus*, for example in pre-operative cardiac patients as well as to screen for carriage of Meticillin Resistant *Staphylococcus aureus* (MRSA) refer to [B 29 - Investigation of Specimens for Screening for MRSA](http://www.hpa.org.uk/SMI/pdf/Bacteriology)51.

*S. aureus* has sporadically been reported as a cause of peritonsillar abscess. Pus may be aspirated from the abscess and sent for culture (refer to [B 14 - Investigation of Abscesses and Post-Operative Wound and Deep-Seated Wound Infections](http://www.hpa.org.uk/SMI/pdf/Bacteriology)).

Epiglottitis

Epiglottitis is an inflammation of the epiglottis. It commonly affects children and is associated with fever, hoarseness of voice, stridor and difficulty in swallowing. Most cases of epiglottitis in young children under the age of five used to be caused by *Haemophilus influenzae* type b but since the introduction of *H. influenzae* type b (Hib) vaccine in October 1992, a decline in the number of cases of acute epiglottitis in children has occurred, although a minor resurgence of cases was seen in the early part of the 21st century52. Epiglottitis in adults is unusual and the numbers have been largely unaffected by the vaccination programme, in keeping with the more diverse range of causative organisms53.

Capsulated *H. influenzae* type b, as well as other types should still be considered when treating epiglottitis, even in immunised children. Acute epiglottitis in young children is a rapidly progressive cellulitis of the epiglottis and surrounding tissues and may result in complete airways obstruction. Because trauma from the swab may precipitate obstruction, throat swabs are contraindicated in cases of suspected acute epiglottitis. Blood cultures should be taken in all cases of suspected epiglottitis.

Treatment of *H. influenzae* type b invasive disease may not eliminate pharyngeal carriage of the organism. Failure to eradicate upper airway colonisation may impose a risk to the patient and to susceptible family contacts.

Throat swabs to determine upper airway colonisation with *H. influenzae* type b are usually only taken for epidemiological studies.

Other bacterial causes of epiglottitis include Group A beta-haemolytic streptococci, *Pseudomonas* species and *Mycobacterium tuberculosis*. *Candida* species and *Aspergillus* species are seen in immunocompromised patients.

Tonsillitis

Tonsillitis is inflammation of the tonsils, usually due to a viral infection or, less commonly, a bacterial infection. It is a common type of infection in children, although it can sometimes affect adults. Symptoms of tonsillitis include sore throat that can feel worse when swallowing, fever, coughing and headache. These symptoms will usually pass within 3-4 days.

Quinsy (peritonsillar abscess) is an acute infection located between the capsule of the palatine tonsil and the superior constrictor muscle of the pharynx54. Peritonsillar abscess is rare and forms, usually on one side of the throat only, with the swelling behind the tonsil near the back of the roof of the mouth. Symptoms are similar to that of tonsillitis, including dribbling, generally feeling unwell and neck swelling because of the abscess. This disease can occur in all age groups, but teenagers and young adults are most frequently affected1. It is usually caused by *Streptococcus* species as a complication of tonsillitis. The *Streptococcus* *anginosus* group (also known as *Streptococcus milleri* group) and Group A Streptococci have been established as key organisms in peritonsillar abscess55.

*Fusobacterium necrophorum* and *Fusobacterium nucleatum* are also comparatively common causes of quinsy37,55. Anaerobic organisms predominantly isolated in peritonsillar abscesses include *Prevotella, Porphyromonas* and *Peptostreptococcus* species56,57.

*S. aureus* has sporadically been reported as a cause of quinsy. Pus may be aspirated from the abscess and sent for culture (refer to [B 14 - Investigation of Abscesses and Deep-Seated Wound Infections](http://www.hpa.org.uk/SMI/pdf/Bacteriology)).

*Arcanobacterium haemolyticum* has been associated with tonsillitis, pharyngitis and may cause a rash in young adults and occasionally in children16,31. It is suggested that in cases of treatment failure and recurrent tonsillitis, isolation of *A. haemolyticum* should be considered.

Laryngitis

Laryngitis is inflammation of the larynx (voice box). In most cases, laryngitis is caused by a viral infection (such as a cold), or voice strain or by bacteria such as *Corynebacterium diphtheriae*, although this is rare3. There is also a recent case report that suggests that MRSA has been implicated in laryngitis58. This eases without treatment within a week. This is known as acute laryngitis. Symptoms of laryngitis include hoarseness, loss of voice and sore throat.

Laryngitis can occasionally have other causes, such as smoking, alcohol misuse, voice overuse, reflux of acid from the stomach (also called gastroesophageal reflux disease (GERD)), rare infections or allergies, or inhalation or irritants or chemicals59. The symptoms do last much longer. This is known as chronic laryngitis.

Other less common causes of chronic laryngitis are bacterial (Group A streptococci, *Streptococcus pneumoniae, Haemophilus influenzae* and *Mycobacterium tuberculosis*) or fungal (*Candida* species, *Blastomyces* species) infections and parasite infections.

For viruses that may be isolated from throat swabs, refer to [G 8 – Respiratory Viruses.](http://www.hpa.org.uk/SMI/pdf/clinicalguidance)

**Screening of neonates**

Surveillance screening of neonates may include a throat swab.

Technical Information/Limitations

Limitations of UK SMIs

The recommendations made in UK SMIs are based on evidence (eg sensitivity and specificity) where available, expert opinion and pragmatism, with consideration also being given to available resources. Laboratories should take account of local requirements and undertake additional investigations where appropriate. Prior to use, laboratories should ensure that all commercial and in-house tests have been validated and are fit for purpose.

Selective Media in Screening Procedures

Selective media which does not support the growth of all circulating strains of organisms may be recommended based on the evidence available. A balance therefore must be sought between available evidence, and available resources required if more than one media plate is used.

Specimen Containers60,61

SMIs use the term “CE marked leak proof container” to describe containers bearing the CE marking used for the collection and transport of clinical specimens. The requirements for specimen containers are given in the EU in vitro Diagnostic Medical Devices Directive (98/79/EC Annex 1 B 2.1) which states: “The design must allow easy handling and, where necessary, reduce as far as possible contamination of, and leakage from, the device during use and, in the case of specimen receptacles, the risk of contamination of the specimen. The manufacturing processes must be appropriate for these purposes”.

Incubation

The duration of incubation can affect the throat culture result. Once plated, a culture should be incubated at 35°C–37°C for 18–24 hours before reading. Additional incubation overnight at room temperature may identify a number of additional positive throat culture results. However, although initial therapeutic decisions may be made on the basis of overnight culture, it is advisable to re-examine plates at 48 hours that yield negative results at 24 hours62.

1 Safety Considerations60,61,63-77

1.1 Specimen Collection, Transport and Storage60,61,63-66

Use aseptic technique.

Collect specimens in appropriate CE marked leak proof containers and transport in sealed plastic bags.

Collect swabs into appropriate transport medium and transport in sealed plastic bags.

Compliance with postal, transport and storage regulations is essential.

1.2 Specimen Processing60,61,63-77

**Hazard Group 2 Organisms**

*C. diphtheriae* and *C. ulcerans* are in Hazard group 2; suspected and known isolates of *C. diphtheriae* /*C. ulcerans* should always be handled in a microbiological safety cabinet. Sometimes the nature of the work may dictate that full containment Level 3 conditions should be used eg for the propagation of *C. diphtheriae /C. ulcerans* in order to comply with COSHH 2004 Schedule 3 (4e). For the urease test a urea slope is considered safer than a liquid medium.

*N. gonorrhoeae* and *N. meningitidis* are also Hazard group 2 organisms. Although for *N. meningitidis*, the processing of diagnostic samples can be carried out in a microbiological safety cabinet Level 2 but due to the severity of the disease and the risks associated with generating aerosols, any manipulation of suspected isolates of *N. meningitidis* should always be undertaken in a microbiological safety cabinet until *N. meningitidis* has been ruled out (as must any laboratory procedure giving rise to infectious aerosols)69.

*Haemophilus influenzae* is a Hazard Group 2 organism, and, and in some cases the nature of the work may dictate full Containment Level 3 conditions 78.

**Hazard Group 3 Organisms**

*F. tularensis* is a Hazard group 3 organism, one of the most potent pathogens known in human medicine and evokes great concern as a bioterrorism agent 79.

Laboratory procedures that give rise to infectious aerosols must be conducted in a microbiological safety cabinet 69.

Refer to current guidance on the safe handling of all organisms documented in this SMI.

The above guidance should be supplemented with local COSHH and risk assessments.

2 Specimen Collection

2.1 Type of Specimens

Throat swab, posterior pharyngeal swab, nasopharyngeal swab, pharyngeal washings, pus aspirate, oropharyngeal swab, throat gargle

2.2 Optimal Time and Method of Collection80

For safety considerations refer to Section 1.1.

Collect specimens before antimicrobial therapy where possible80.

Unless otherwise stated, swabs for bacterial and fungal culture should be placed in appropriate transport medium81-85.

Throat swabs should be taken from the tonsillar area and/or posterior pharynx, avoiding the tongue and uvula.

Throat culture should not be taken if the epiglottis is inflamed as sampling may cause serious respiratory obstruction.

Collect specimens other than swabs into appropriate CE marked leak proof containers and place in sealed plastic bags.

2.3 Adequate Quantity and Appropriate Number of Specimens80

Numbers and frequency of specimen collection are dependent on clinical condition of patient.

3 Specimen Transport and Storage 60,61

3.1 Optimal Transport and Storage Conditions

For safety considerations refer to Section 1.1.

Specimens should be transported and processed as soon as possible80.

If processing is delayed, refrigeration is preferable to storage at ambient temperature 80.

Ideally, inoculation of specimens for *N. gonorrhoeae* should be made directly on to culture media at the time of collection and these should be incubated without delay. Transport time should be as short as possible86.

4 Specimen Processing/Procedure60,61

4.1 Test Selection

N/A

4.2 Appearance

N/A

4.3 Sample Preparation

For safety considerations refer to Section 1.2.

4.4 Microscopy

4.4.1 Standard

Stain for Vincent's organism if clinically indicated (refer to [TP 39 – Staining Procedures](http://www.hpa.org.uk/SMI/pdf/testprocedures)).

4.4.2 Supplementary / Preparation of smears

N/A

4.5 Culture and Investigation

Inoculate each agar plate with swab (refer to [Q 5 – Inoculation of Culture Media in Bacteriology](http://www.hpa.org.uk/SMI/pdf/qualityguidance)).

4.5.1 Culture media, conditions and organisms

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Clinical details/**  **conditions** | **Specimen** | **Standard media** | **Incubation** | | | **Cultures read** | **Target organism(s)‡** |
| **Temp °C** | **Atmos** | **Time** |
| Pharyngitis (Sore throat)  Epiglottitis  Tonsillitis  Laryngitis | Throat swab | Blood agar7\*  **OR** | 35-37 | Anaerobic | 18-24hr | ≥18hr | Lancefield group A, C and G streptococci |
| Staph/Strep selective agar\*\* 87,88 | 35–37 | Aerobic | 18-48hr | ≥24hr |
| For these situations, add the following: | | | | | | | |
| **Clinical details/**  **conditions** | **Specimen** | **Supplementary media** | **Incubation** | | | **Cultures read** | **Target organism(s)** |
| **Temp °C** | **Atmos** | **Time** |
| Membrane formation or membranous pharyngitis/tonsillitis  Foreign travel to high risk area | Throat swab  **OR**  Nasopharnygeal swab | Hoyle's tellurite agar | 35-37 | Air | 18-48hr | daily | Toxigenic  *C. diphtheriae* and *C. ulcerans* |
| *S. aureus* carriage | Throat swab | Blood agar\*\* | 35-37 | 5-10% CO2 | 18-24hr | 18hr | *S. aureus* |
| GUM clinic,  gonorrhoea,  *N. meningitidis* case or contact | posterior pharyngeal swab  **OR**  Nasopharyngeal swab | GC selective agar | 35-37 | 5-10% CO2 | 40-48hr | 40hr | *N. gonorrhoeae*  *N. meningitidis* |
| Treatment failure and recurrent tonsillitis | Throat swab | Blood agar | 35-37 | 5-10% CO2 | 40-48hr\*\*\* | 48hr | *A. haemolyticum* 32 |
| Epiglottitis | Throat swab | Chocolate agar | 35-37 | 5-10% CO2 | 24 -48hr | daily | *H. influenzae* |
| Diabetes, Immunosuppressed, Oral candidosis | Throat swab  **OR**  Oropharyngeal swab | Sabouraud agar  **OR**  Chromogenic agar# 89-91 | 35-37 | Air | 40-48hr | ≥40hr | Yeasts  Mould |
| **Clinical details/**  **conditions** | **Specimen** | **Optional media** | **Incubation** | | | **Cultures read** | **Target organism(s)** |
| **Temp °C** | **Atmos** | **Time** |
| Persistent sore throat or Quinsy | Pus aspirate  **OR**  Throat swab | Fastidious Anaerobic Agar (FAA) containing nalidixic acid and vancomycin | 35-37 | Anaerobic | 5-7 d | ≥48hr | *F. necrophorum* 37 |
| Other organisms for consideration – MRSA ([B 29 - Investigation of Specimens for Screening for MRSA](http://www.hpa.org.uk/SMI/pdf/Bacteriology)) and non-toxigenic *C. diphtheriae.*  *Francisella tularensis* and *Yersinia enterocolitica* although uncommon causes of throat related infections, may be considered. *F. tularensis* has been isolated from oropharyngeal specimens, pharyngeal washings, sputum specimens, and even fasting gastric aspirates. It has also only occasionally been isolated from blood42.  Other predominant anaerobic organisms isolated in peritonsillar abscesses are *Prevotella, Porphyromonas* and *Peptostreptococcus* species 56,57. | | | | | | | |
| \*Alternatively, the blood agar could also be incubated in 5-10% CO2 at 35-37°C for 18 – 24hr 6,62  \*\**Staphylococcus/Streptococcus* selective agar may be used for Lancefield group streptococci. The duration of incubation can affect throat culture result and so for increased isolation rate of Lancefield group A streptococci, further incubation of culture plates for 40-48hr is done and then re-examined 62.  \*\*\*May be extended to 72hr.  # There is a wide range of commercially available chromogenic culture media for the isolation of yeasts. Manufacturer’s instructions on use must be followed 89,90.  ‡-For appearance of relevant target organism see individual SMIs for organism identification. | | | | | | | |

4.6 Identification

Refer to individual SMIs for organism identification.

4.6.1 Minimum level of identification in the laboratory

|  |  |
| --- | --- |
| [*C. diphtheriae*](http://www.hpa.org.uk/SMI/pdf/Identification) | species level; urgent toxigenicity test / refer to Ref Lab |
| [*C. ulcerans*](http://www.hpa.org.uk/SMI/pdf/Identification) | species level; urgent toxigenicity test / refer to Ref Lab |
| [*H. influenzae*](http://www.hpa.org.uk/SMI/pdf/Identification) | species level; type b or not if epiglottitis, refer to Ref Lab |
| [β haemolytic streptococci](http://www.hpa.org.uk/SMI/pdf/identification) | Lancefield group level |
| [*A. haemolyticum*](http://www.hpa.org.uk/SMI/pdf/Identification) | species level |
| [*N. gonorrhoeae*](http://www.hpa.org.uk/SMI/pdf/Identification) | species level |
| [*N. meningitidis*](http://www.hpa.org.uk/SMI/pdf/Identification) | species level |
| [*S. aureus*](http://www.hpa.org.uk/SMI/pdf/Identification) | species level |
| Yeasts | "yeasts" level \* |
| [*Fusobacterium*](http://www.hpa.org.uk/SMI/pdf/identification)species | species level |
| \* Yeast and fungal isolates from patients who are immunocompromised usually require identification and susceptibility testing. | |

Organisms may be further identified if this is clinically or epidemiologically indicated.

Note: All work on suspected isolates of *C. diphtheriae* which is likely to generate aerosols must be performed in a safety cabinet.

A medical microbiologist must be informed of all suspected isolates of *C. diphtheriae* as soon as possible, so that a risk assessment can be undertaken for rapid referral for toxin testing. Toxigenicity testing is available and undertaken only by the Respiratory and Vaccine Preventable Bacteria Reference Unit (RVPBRU) PHE Colindale.

4.7 Antimicrobial Susceptibility Testing

Refer to [British Society for Antimicrobial Chemotherapy (BSAC)](http://bsac.org.uk/) and/or [EUCAST](http://www.eucast.org/) guidelines.

4.8 Referral for Outbreak Investigations

**Diphtheria**

As diphtheria is a notifiable disease in the UK, for public health management of cases, contacts and outbreaks, all suspected cases should be notified immediately to the local Public Health England Centres.

All clinically significant isolates should be notified by the diagnostic laboratories to ensure urgent initiation of proper procedures and all such isolates should be referred to the national reference laboratory for toxigenicity testing.

**Group A Streptococci (GAS) infection92**

Clinicians, microbiologists and health protection teams (HPTs) should be mindful of potential increases in invasive disease and maintain a high index of suspicion in relevant patients as early recognition and prompt initiation of specific and supportive therapy can be lifesaving. Invasive disease isolates and those from suspected clusters or outbreaks should be submitted immediately to the Respiratory and Vaccine Preventable Bacteria Reference Unit at Public Health England, 61 Colindale Avenue, London NW9 5EQ. For more information, refer to <http://www.hpa.org.uk/Topics/InfectiousDiseases/InfectionsAZ/StreptococcalInfections/Guidelines>.

4.9 Referral to Reference Laboratories

For information on the tests offered, turnaround times, transport procedure and the other requirements of the reference laboratory [click here for user manuals and request forms](http://www.hpa.org.uk/ProductsServices/MicrobiologyPathology/MicrobiologicalTestsAndServices/cfiIndexTestsServicesMicrobio/).

Organisms with unusual or unexpected resistance and whenever there is a laboratory or clinical problem, or anomaly that requires elucidation should be sent to the appropriate reference laboratory.

Contact appropriate devolved national reference laboratory for information on the tests available, turnaround times, transport procedure and any other requirements for sample submission:

England and Wales <http://www.hpa.org.uk/webw/HPAweb&Page&HPAwebAutoListName/Page/1158313434370?p=1158313434370>

Scotland

<http://www.hps.scot.nhs.uk/reflab/index.aspx>

Northern Ireland

<http://www.publichealth.hscni.net/directorate-public-health/health-protection>

5 Reporting Procedure

5.1 Microscopy

Stain for Vincent's organisms: report on Vincent's organisms detected.

**5.1.1 Microscopy reporting time**

Report results for Vincent's organisms as soon as available within 24hr of receipt.

5.2 Culture

**Negatives**

"β-haemolytic streptococci of Lancefield group A, C and G not isolated".

"*Corynebacterium diphtheriae* not isolated".

Also, report results of supplementary investigations.

**Positives**

Report clinically significant organisms isolated.

**5.2.1 Culture reporting time**

Clinically urgent culture results to be telephoned or sent electronically.

Written report, 16–72hr stating, if appropriate, that a further report will be issued.

Supplementary investigations, toxigenicity testing of *C. diphtheriae*.

5.3 Antimicrobial Susceptibility Testing

Report susceptibilities as clinically indicated. Prudent use of antimicrobials according to local and national protocols is recommended.

6 Notification to PHE 93,94 or Equivalent in the Devolved Administrations 18,95-98

The Health Protection (Notification) regulations 2010 require diagnostic laboratories to notify Public Health England (PHE) when they identify the causative agents that are listed in Schedule 2 of the Regulations. Notifications must be provided in writing, on paper or electronically, within seven days. Urgent cases should be notified orally and as soon as possible, recommended within 24 hours. These should be followed up by written notification within seven days.

For the purposes of the Notification Regulations, the recipient of laboratory notifications is the local PHE Health Protection Team. If a case has already been notified by a registered medical practitioner, the diagnostic laboratory is still required to notify the case if they identify any evidence of an infection caused by a notifiable causative agent.

Notification under the Health Protection (Notification) Regulations 2010 does not replace voluntary reporting to PHE. The vast majority of NHS laboratories voluntarily report a wide range of laboratory diagnoses of causative agents to PHE and many PHE Health protection Teams have agreements with local laboratories for urgent reporting of some infections. This should continue.

**Note:** The Health Protection Legislation Guidance (2010) includes reporting of Human Immunodeficiency Virus (HIV) & Sexually Transmitted Infections (STIs), Healthcare Associated Infections (HCAIs) and Creutzfeldt–Jakob disease (CJD) under ‘Notification Duties of Registered Medical Practitioners’: it is not noted under ‘Notification Duties of Diagnostic Laboratories’.

<http://www.hpa.org.uk/Topics/InfectiousDiseases/InfectionsAZ/HealthProtectionRegulations/>

Other arrangements exist in [Scotland](http://www.scotland.gov.uk/Topics/Health/Policy/Public-Health-Act/Implementation/Guidance/Guidance-Part2)95,96, [Wales](http://www.wales.nhs.uk/sites3/page.cfm?orgid=457&pid=48544)97 and [Northern Ireland](http://www.publichealthagency.org/directorate-public-health/health-protection/notifications-infectious-diseases)98.

Appendix: Investigation of Throat Related Specimens



\*Staphylococcus/Streptococcus selective agars may be used for Lancefield group streptococci

References

1. Rafei K, Lichenstein R. Airway infectious disease emergencies. Pediatr Clin North Am 2006;53:215-42.

2. Grief SN. Upper respiratory infections. Prim Care 2013;40:757-70.

3. Shulman ST, Bisno AL, Clegg HW, Gerber MA, Kaplan EL, Lee G, et al. Clinical practice guideline for the diagnosis and management of group A streptococcal pharyngitis: 2012 update by the Infectious Diseases Society of America. Clin Infect Dis 2012;55:1279-82.

4. Kujala GA, Doshi H, Brick JE. Rheumatic fever and poststreptococcal glomerulonephritis: a case report. Arthritis Rheum 1989;32:236-9.

5. Johnson DR, Stevens DL, Kaplan EL. Epidemiologic analysis of group A streptococcal serotypes associated with severe systemic infections, rheumatic fever, or uncomplicated pharyngitis. J Infect Dis 1992;166:374-82.

6. Turner JC, Hayden FG, Lobo MC, Ramirez CE, Murren D. Epidemiologic evidence for Lancefield group C beta-hemolytic streptococci as a cause of exudative pharyngitis in college students. J Clin Microbiol 1997;35:1-4.

7. Cimolai N, Elford RW, Bryan L, Anand C, Berger P. Do the beta-hemolytic non-group A streptococci cause pharyngitis?[comment]. [Review] [145 refs]. Rev Infect Dis 1988;10:587-601.

8. Fox K, Turner J, Fox A. Role of beta-hemolytic group C streptococci in pharyngitis: incidence and biochemical characteristics of Streptococcus equisimilis and Streptococcus anginosus in patients and healthy controls. J Clin Microbiol 1993;31:804-7.

9. Turner JC, Fox A, Fox K, Addy C, Garrison CZ, Herron B, et al. Role of group C beta-hemolytic streptococci in pharyngitis: epidemiologic study of clinical features associated with isolation of group C streptococci. J Clin Microbiol 1993;31:808-11.

10. Martin NJ, Kaplan EL, Gerber MA, Menegus MA, Randolph M, Bell K, et al. Comparison of epidemic and endemic group G streptococci by restriction enzyme analysis. Journal of Clinical Microbiology 1990;28:1881-6.

11. Efstratiou A. Pyogenic streptococci of Lancefield groups C and G as pathogens in man. Soc Appl Bacteriol Symp Ser 1997;26:72S-9S.

12. Efstratiou A, George RC. Laboratory guidelines for the diagnosis of infections caused by Corynebacterium diphtheriae and C. ulcerans. World Health Organization. Commun Dis Public Health 1999;2:250-7.

13. Efstratiou A, George RC, Begg NT. Non-toxigenic Corynebacterium diphtheriae var gravis in England.[comment]. Lancet 1993;341:1592-3.

14. Efstratiou A, Tiley SM, Sangrador A, Greenacre E, Cookson BD, Chen SC, et al. Invasive disease caused by multiple clones of Corynebacterium diphtheriae. Clin Infect Dis 1993;17:136.

15. De Zoysa A, Efstratiou A. Eighth International Meeting of the European Laboratory Working Group on Diphtheria and the Diphtheria Surveillance Network - June 2004: Progress is needed to sustain control of diphtheria in European Region. Euro Surveill 2004;9.

16. Karpathios T, Drakonaki S, Zervoudaki A, Coupari G, Fretzayas A, Kremastinos J, et al. Arcanobacterium haemolyticum in children with presumed streptococcal pharyngotonsillitis or scarlet fever. J Pediatr 1992;121:735-7.

17. Salisbury D, Ramsay M, Noakes K, editors. Immunisation against infectious disease 2006 - The Green Book. Updated 04 November 2013. 3rd ed. Great Britain: The Stationery Office; 2013. p. 1-514

18. Diphtheria Guidelines Working Group. *Public Health Control and Management of Diphtheria in England and Wales - Interim Guidelines*. Public Health England. 1-4-2014. p. 1-43

19. Bostock AD, Gilbert FR, Lewis D, Smith DC. Corynebacterium ulcerans infection associated with untreated milk. J Infect 1984;9:286-8.

20. Bernard K. The genus corynebacterium and other medically relevant coryneform-like bacteria. J Clin Microbiol 2012;50:3152-8.

21. Hogg RA, Wessels J, Hart J, Efstratiou A, De ZA, Mann G, et al. Possible zoonotic transmission of toxigenic Corynebacterium ulcerans from companion animals in a human case of fatal diphtheria. Vet Rec 2009;165:691-2.

22. De Zoysa A, Hawkey PM, Engler K, George R, Mann G, Reilly W, et al. Characterization of toxigenic Corynebacterium ulcerans strains isolated from humans and domestic cats in the United Kingdom. J Clin Microbiol 2005;43:4377-81.

23. Hart J., Efstratiou A, Cowcroft N. Human Diphtheria from Dogs? Ninth International Meeting of the European Laboratory Working Group on Diphtheria and the Third DIPNET Meeting. European Workshop on Laboratory Diagnosis of Diphtheria DIPNET, Diphtheria Surveillnce Network HPA Centre For Infections 2006;15-7.

24. Cerdeno-Tarraga AM, Efstratiou A, Dover LG, Holden MT, Pallen M, Bentley SD, et al. The complete genome sequence and analysis of Corynebacterium diphtheriae NCTC13129. Nucleic Acids Res 2003;31:6516-23.

25. Pappenheimer AM, Jr., Murphy JR. Studies on the molecular epidemiology of diphtheria. Lancet 1983;2:923-6.

26. Markina SS, Maksimova NM, Vitek CR, Bogatyreva EY, Monisov AA. Diphtheria in the Russian Federation in the 1990s. J Infect Dis 2000;181 Suppl 1:S27-S34.

27. Nekrassova LS, Chudnaya LM, Marievski VF, Oksiuk VG, Gladkaya E, Bortnitska II, et al. Epidemic diphtheria in Ukraine, 1991-1997. J Infect Dis 2000;181 Suppl 1:S35-S40.

28. Wagner KS, White JM, Neal S, Crowcroft NS, Kupreviciene N, Paberza R, et al. Screening for Corynebacterium diphtheriae and Corynebacterium ulcerans in patients with upper respiratory tract infections 2007-2008: a multicentre European study. Clin Microbiol Infect 2011;17:519-25.

29. Wagner KS, White JM, Crowcroft NS, De MS, Mann G, Efstratiou A. Diphtheria in the United Kingdom, 1986-2008: the increasing role of Corynebacterium ulcerans. Epidemiol Infect 2010;138:1519-30.

30. Finegold S. Anaerobic Gram-Negative Rods: Bacteroides, Prevotella, Porphyomonas, Fusobacterium, Bilophila, Sutterella. In: Gorbach SL, Bartlett JG, Blacklow NR, editors. Infectious Diseases. 2nd ed. Philadelphia: WB Saunders Company; 1998. p. 1904-15.

31. Gaston DA, Zurowski SM. Arcanobacterium haemolyticum pharyngitis and exanthem. Three case reports and literature review. Archiv Dermatol 1996;132:61-4.

32. Cummings LA, Wu WK, Larson AM, Gavin SE, Fine JS, Coyle MB. Effects of media, atmosphere, and incubation time on colonial morphology of Arcanobacterium haemolyticum. J Clin Microbiol 1993;31:3223-6.

33. Abildgaard N, Haugaard L, Bendix K. Nonfatal total expulsion of the distal oesophagus due to invasive candida oesophagitis. Scand J Infect Dis 1993;25:153-6.

34. Tavitian A, Raufman JP, Rosenthal LE. Oral candidiasis as a marker for esophageal candidiasis in the acquired immunodeficiency syndrome. Ann Intern Med 1986;104:54-5.

35. Andersen LI, Frederiksen HJ, Appleyard M. Prevalence of esophageal Candida colonization in a Danish population: special reference to esophageal symptoms, benign esophageal disorders, and pulmonary disease. J Infect Dis 1992;165:389-92.

36. Riordan T. Human Infection with Fusobacterium necrophorum (Necrobacillosis), with a focus on Lemierre's syndrome. Clin Micobiol Rev 2007;622-59.

37. Batty A, Wren MW, Gal M. Fusobacterium necrophorum as the cause of recurrent sore throat: comparison of isolates from persistent sore throat syndrome and Lemièrre's disease. J Infect 2005;51:299-306.

38. Aliyu SH, Marriott RK, Curran MD, Parmar S, Bentley N, Brown NM, et al. Real-time PCR investigation into the importance of Fusobacterium necrophorum as a cause of acute pharyngitis in general practice. J Med Microbiol 2004;53:1029-35.

39. Brown RT, Lossick JG, Mosure DJ, Smeltzer MP, Cromer BA. Pharyngeal gonorrhea screening in adolescents: is it necessary? Pediatrics 1989;84:623-5.

40. Jones RM, Nicas M, Hubbard A, Sylvester MD, Reingold A. The Infectious Dose of *Francisella tularensis* (Tularemia). Applied Biosafety 2005;10:227-39.

41. Tarnvik A, Berglund L. Tularaemia. Eur Respir J 2003;21:361-73.

42. Tacket CO, Davis BR, Carter GP, Randolph JF, Cohen ML. Yersinia enterocolitica pharyngitis. Ann Intern Med 1983;99:40-2.

43. Fenwick SG. Pharyngitis and infections with Yersinia enterocolitica. N Z Med J 1992;105:112.

44. . Control of meningococcal disease: guidance for consultants in communicable disease control. PHLS Meningococcal Infections Working Group and Public Health Medicine Environmental Group. Commun Dis Rep CDR Rev 1995;5:R189-R195.

45. Roberts J, Greenwood B, Stuart J. Sampling methods to detect carriage of Neisseria meningitidis; literature review. Journal of Infection 2009;58:103-7.

46. Esposito S, Zampiero A, Terranova L, Montinaro V, Peves RW, Scala A, et al. Comparison of posterior pharyngeal wall and nasopharyngeal swabbing as a means of detecting the carriage of Neisseria meningitidis in adolescents. Eur J Clin Microbiol Infect Dis 2013;32:1129-33.

47. Kaczmarski EB, Cartwright KA. Control of meningococcal disease: guidance for microbiologists: CCDC. Consultant in Communicable Disease Control, England. Communicable Disease Report CDR Review 1995;5:R196-R198.

48. Cartwright KA, Jones DM. Value of throat swabs from index cases of meningococcal meningitis.[comment]. J Clin Pathol 1990;43:438.

49. Jewes L, Norman P, McKendrick MW. Value of throat swabs in meningococcal meningitis.[comment]. J Clin Pathol 1989;42:1229.

50. Sippel JE, Girgis NI. Throat culture from patients with meningococcal meningitis. J Clin Pathol 1990;43:610-1.

51. Marshall C, Spelman D. Is throat screening necessary to detect meticillin-resistant *Staphylococcus aureus* colonization in patients upon admission to an intensive care unit? Journal of Clinical Microbiology 2007;45:3855.

52. Wagle A, Jones RM. Acute epiglottitis despite vaccination with haemophilus influenzae type b vaccine. Paediatric Anaesthesia 1999;9:549-50.

53. McVernon J, Slack MP, Ramsay ME. Changes in the epidemiology of epiglottitis following introduction of Haemophilus influenzae type b (Hib) conjugate vaccines in England: a comparison of two data sources. Epidemiol Infect 2006;134:570-2.

54. Hsiao HJ, Huang YC, Hsia SH, Wu CT, Lin JJ. Clinical features of peritonsillar abscess in children. Pediatr Neonatol 2012;53:366-70.

55. Wang SM. Peritonsillar abscess: cool "hot potato". Pediatr Neonatol 2012;53:325-6.

56. Brook I. Anaerobic bacteria in upper respiratory tract and head and neck infections: microbiology and treatment. Anaerobe 2012;18:214-20.

57. Brook I. Microbiology and management of peritonsillar, retropharyngeal, and parapharyngeal abscesses. J Oral Maxillofac Surg 2004;62:1545-50.

58. Liakos T, Kaye K, Rubin AD. Methicillin-resistant Staphylococcus aureus laryngitis. Ann Otol Rhinol Laryngol 2010;119:590-3.

59. Ahmed TF, Khandwala F, Abelson TI, Hicks DM, Richter JE, Milstein C, et al. Chronic laryngitis associated with gastroesophageal reflux: prospective assessment of differences in practice patterns between gastroenterologists and ENT physicians. Am J Gastroenterol 2006;101:470-8.

60. European Parliament. UK Standards for Microbiology Investigations (SMIs) use the term "CE marked leak proof container" to describe containers bearing the CE marking used for the collection and transport of clinical specimens. The requirements for specimen containers are given in the EU in vitro Diagnostic Medical Devices Directive (98/79/EC Annex 1 B 2.1) which states: "The design must allow easy handling and, where necessary, reduce as far as possible contamination of, and leakage from, the device during use and, in the case of specimen receptacles, the risk of contamination of the specimen. The manufacturing processes must be appropriate for these purposes".

61. Official Journal of the European Communities. Directive 98/79/EC of the European Parliament and of the Council of 27 October 1998 on *in vitro* diagnostic medical devices. 7-12-1998. p. 1-37.

62. Kellogg JA. Suitability of throat culture procedures for detection of group A streptococci and as reference standards for evaluation of streptococcal antigen detection kits. J Clin Microbiol 1990;28:165-9.

63. Health and Safety Executive. Safe use of pneumatic air tube transport systems for pathology specimens. 9/99.

64. Department for transport. Transport of Infectious Substances, 2011 Revision 5. 2011.

65. World Health Organization. Guidance on regulations for the Transport of Infectious Substances 2013-2014. 2012.

66. Home Office. Anti-terrorism, Crime and Security Act. 2001 (as amended).

67. Advisory Committee on Dangerous Pathogens. The Approved List of Biological Agents. Health and Safety Executive. 2013. p. 1-32

68. Advisory Committee on Dangerous Pathogens. Infections at work: Controlling the risks. Her Majesty's Stationery Office. 2003.

69. Advisory Committee on Dangerous Pathogens. Biological agents: Managing the risks in laboratories and healthcare premises. Health and Safety Executive. 2005.

70. Advisory Committee on Dangerous Pathogens. Biological Agents: Managing the Risks in Laboratories and Healthcare Premises. Appendix 1.2 Transport of Infectious Substances - Revision. Health and Safety Executive. 2008.

71. Centers for Disease Control and Prevention. Guidelines for Safe Work Practices in Human and Animal Medical Diagnostic Laboratories. MMWR Surveill Summ 2012;61:1-102.

72. Health and Safety Executive. Control of Substances Hazardous to Health Regulations. The Control of Substances Hazardous to Health Regulations 2002. 5th ed. HSE Books; 2002.

73. Health and Safety Executive. Five Steps to Risk Assessment: A Step by Step Guide to a Safer and Healthier Workplace. HSE Books. 2002.

74. Health and Safety Executive. A Guide to Risk Assessment Requirements: Common Provisions in Health and Safety Law. HSE Books. 2002.

75. Health Services Advisory Committee. Safe Working and the Prevention of Infection in Clinical Laboratories and Similar Facilities. HSE Books. 2003.

76. British Standards Institution (BSI). BS EN12469 - Biotechnology - performance criteria for microbiological safety cabinets. 2000.

77. British Standards Institution (BSI). BS 5726:2005 - Microbiological safety cabinets. Information to be supplied by the purchaser and to the vendor and to the installer, and siting and use of cabinets. Recommendations and guidance. 24-3-2005. p. 1-14

78. Jacobson JT, Orlob RB, Clayton JL. Infections acquired in cinical laboratories in Utah. Journal of Clinical Microbiology 1985;21:486-9.

79. Dennis DT, Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, et al. Tularemia as a biological weapon: medical and public health management. JAMA 2001;285:2763-73.

80. Baron EJ, Miller JM, Weinstein MP, Richter SS, Gilligan PH, Thomson RB, Jr., et al. A Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2013 Recommendations by the Infectious Diseases Society of America (IDSA) and the American Society for Microbiology (ASM). Clin Infect Dis 2013;57:e22-e121.

81. Rishmawi N, Ghneim R, Kattan R, Ghneim R, Zoughbi M, Abu-Diab A, et al. Survival of fastidious and nonfastidious aerobic bacteria in three bacterial transport swab systems. J Clin Microbiol 2007;45:1278-83.

82. Barber S, Lawson PJ, Grove DI. Evaluation of bacteriological transport swabs. Pathology 1998;30:179-82.

83. Van Horn KG, Audette CD, Sebeck D, Tucker KA. Comparison of the Copan ESwab system with two Amies agar swab transport systems for maintenance of microorganism viability. J Clin Microbiol 2008;46:1655-8.

84. Nys S, Vijgen S, Magerman K, Cartuyvels R. Comparison of Copan eSwab with the Copan Venturi Transystem for the quantitative survival of *Escherichia coli, Streptococcus agalactiae* and *Candida albicans*. Eur J Clin Microbiol Infect Dis 2010;29:453-6.

85. Tano E, Melhus A. Evaluation of three swab transport systems for the maintenance of clinically important bacteria in simulated mono- and polymicrobial samples. APMIS 2011;119:198-203.

86. Lewis B. Identification of Aerobic Bacteria from Genital Specimens. In: Isenberg HD, editor. Clinical Microbiology Procedures Handbook.Vol 1. Washington D.C: American Society for Microbiology; 1992. p. Section-1.

87. Petts DN. Colistin-oxolinic acid-blood agar: a new selective medium for streptococci. J Clin Microbiol 1984;19:4-7.

88. Dierksen KP, Tagg JR. Haemolysin-deficient variants of Streptococcus pyogenes and S. dysgalactiae subsp. equisimilis may be overlooked as aetiological agents of pharyngitis. J Med Microbiol 2000;49:811-6.

89. Murray CK, Beckius ML, Green JA, Hospenthal DR. Use of chromogenic medium in the isolation of yeasts from clinical specimens. J Med Microbiol 2005;54:981-5.

90. Perry JD, Freydiere AM. The application of chromogenic media in clinical microbiology. J Appl Microbiol 2007;103:2046-55.

91. Willinger B, Hillowoth C, Selitsch B, Manafi M. Performance of Candida ID, a New Chromogenic Medium for Presumptive Identification of *Candida* Species, in Comparison to CHROMagar Candida. Journal of Clinical Microbiology 2001;39:3793-5.

92. . Group A streptococcal infections: seasonal activity, 2013/14. Health Protection Report 2014;8.

93. Public Health England. Laboratory Reporting to Public Health England: A Guide for Diagnostic Laboratories. 2013. p. 1-37.

94. Department of Health. Health Protection Legislation (England) Guidance. 2010. p. 1-112.

95. Scottish Government. Public Health (Scotland) Act. 2008 (as amended).

96. Scottish Government. Public Health etc. (Scotland) Act 2008. Implementation of Part 2: Notifiable Diseases, Organisms and Health Risk States. 2009.

97. The Welsh Assembly Government. Health Protection Legislation (Wales) Guidance. 2010.

98. Home Office. Public Health Act (Northern Ireland) 1967 Chapter 36. 1967 (as amended).

1. # Microbiology is used as a generic term to include the two GMC-recognised specialties of Medical Microbiology (which includes Bacteriology, Mycology and Parasitology) and Medical Virology. [↑](#footnote-ref-1)